Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report

• Published in: OncoTargets and therapy Vol. 13; pp. 7941 - 7948
• Main Authors: Li, Huiying, Yu, Tingting, Lin, Yongjuan, Xie, Yu, Feng, Jie, Huang, Mingmin, Guo, Aibin, Liu, Xiangyu, Yin, Zhenyu
• Format: Journal Article
• Language: English
• Published: Dove 01-01-2020
• Subjects: Case Report
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S259616

Generations of epidermal growth factor receptor tyrosine kinase inhibitors (
EGFR
-TKIs) can significantly improve the outcome of
EGFR
-positive NSCLC patients. However, acquired TKIs-resistant mutations are inevitable. Except the common
EGFR
alterations, more and more rare mutations are revealed by next-generation sequencing (NGS), the clinical significance of which are still unclear. Here, we report an advanced lung adenocarcinoma patient who harbored two novel
EGFR
exon 19 deletions (750_758del and I759S) at the beginning and exhibited a short response to icotinib for 7.0 months. Then, secondary resistance
EGFR
T751_I759delinsS occurred. Chemotherapy combined with bevacizumab and erlotinib was administered in turn but failed. Standard-dose osimertinib (80 mg daily) obtained durable clinical remission for 16 months, and high-dose osimertinib (160 mg daily) further prolonged the survival of 9 months after leptomeningeal metastases (LM) occurring. This study presented the first case of intractable terminal NSCLC in a patient with
EGFR
750_758del, I759S and T751_I759delinsS mutations, who responded positively to osimertinib and achieved a prolonged OS of 52 months, providing a potential therapeutic option for the patients harboring these particular
EGFR
mutations.